Cargando…
Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
BACKGROUND: Leuprorelin is a well-established treatment for prostate cancer (PCa); however, there is limited information on its use in Asian males. This review of English language publications between January 2000 and 2016 describes the outcomes of clinical trials on leuprorelin in Asian males with...
Autores principales: | Chung, Byung Ha, Horie, Shigeo, Chiong, Edmund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125360/ https://www.ncbi.nlm.nih.gov/pubmed/32257971 http://dx.doi.org/10.1016/j.prnil.2019.06.001 |
Ejemplares similares
-
The incidence, mortality, and risk factors of prostate cancer in Asian men
por: Ha Chung, Byung, et al.
Publicado: (2019) -
Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia
por: Han, Wonshik, et al.
Publicado: (2019) -
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008) -
ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD(®)) in Asian men with prostate cancer
por: Malek, Rohan, et al.
Publicado: (2022) -
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)